Article
Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
Journal of neurology, neurosurgery, and psychiatry - 1 Jun 2010
Kasuga Kensaku, Tokutake Takayoshi, Ishikawa Atsushi, Uchiyama Tsuyoshi, Tokuda Takahiko, Onodera Osamu, Nishizawa Masatoyo, Ikeuchi Takeshi
Abstract excerpt
BACKGROUND: The clinical diagnosis of dementia with Lewy bodies (DLB) is made on the basis of consensus criteria; however, the sensitivity of the criteria is relatively low. There are no generally accepted biomarkers to distinguish DLB from other dementias. Here the utility of quantification of alpha-synuclein, beta-amyloid42 (Abeta42) and tau in the CSF of patients with DLB, Alzheimer's disease (AD) and other...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
